Skip to main content

Table 6 Efficacy evaluation during further follow-up. Both groups of patients received formulation A, 30 UI per Kg 3 times per week, subcutaneously.

From: Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

Variable

Day

Group A

Group B

Hemoglobin (g/dL)

0

8.8 ± 1.7

9.0 ± 1.4

 

90

10.5 ± 1.4

11.4 ± 1.6

 

p (90 vs. 0)

0.027

0.004

Hematocrit (%)

0

25.6 ± 4.4

26.9 ± 5.9

 

90

35.5 ± 3.2

36.4 ± 5.1

 

p (90 vs. 0)

< 0.001

0.001

  1. Data are reported as mean ± standard deviation.
  2. Paired tests vs. day 0 were done by paired t test.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us